and for Caucasian men 25.7 per 100,000 males. Based on this statistic, Caucasian men already fare better than the projected goal for 2010 while African American (AA) men have a long way to go to achieve this goal. Prostate cancer education and awareness is very important to eliminate the disparities experienced by AA men. Thus, the purpose of this study is to evaluate the effectiveness of the prostate cancer education kiosk (PCEK). METHODS: Participants were adult AAs who are employees of an HBCU institution. A structured survey instrument assessing participants' demographics and prostate cancer knowledge was employed for the study. Data collection involved three steps: 1) completion of survey before use of kiosk {pre-test}, 2) use of kiosk by participants {post-test}, and 3) completion of survey after use of kiosk {post-test}. RESULTS: Of the 100 participants, most were men (78%), single (53%), had at least a college degree (52%), and between 40-49 years (58%). Men's score on both the pre-test and post-test knowledge scores were higher than women. PCEK was found to significantly improve participants' knowledge. The post-test knowledge score of participants (89.42%) was higher than the pre-test knowledge score of participants (67.92%). CONCLUSION: PCEK offers an effective method to educate AA men about prostate cancer. Future studies should explore the cost-effectiveness of touch screen computers such as PCEK in educating the AA community on diverse health issues.
PCN3 AN ANALYSIS OF OUTPATIENT SERVICE UTILIZATION FOR DELAYED NAUSEA AND VOMITING USING ELECTRONIC MEDICAL RECORDS
Forsyth M 1 , Conner T 1 , Curtis V 1 , Johnsrud M 2 1 US Oncology, Houston, TX, USA, 2 University of Texas at Austin, Austin, TX, USA OBJECTIVES: Delayed chemotherapy-induced nausea and vomiting (CINV) can increase healthcare utilization and decrease patient quality of life. While reports of delayed CINV range from 40-60% with moderately to highly emetogenic regimens, little information is available on utilization of care as a result. To determine the frequency of outpatient service utilization associated with CINV between 24-120 hours following chemotherapy administration during cycles 1-5. METHODS: A retrospective observational design of US Oncology nation-wide iKnowMed electronic medical records (EMR) was employed. The cohort for analysis included patients from four practices in separate states receiving chemotherapy between August 2004 and April 2005. Chemotherapy regimens included one or more of the following five drugs: carboplatin, cisplatin, oxaliplatin, doxorubicin, cyclophosphamide. Failure was defined as one or more of the following events between 24-120 hours following chemotherapy: phone encounters with documentation of CINV; non-chemotherapy office visits for hydration, IV anti-emetic administration, and/or documentation of CINV; oral anti-emetic orders between 24-120 hours. RESULTS: A total of 691 patients were identified as receiving target chemotherapies during cycles 1-5. Mean (std) age was 61 (13) years, and 62% were female. Twenty-six percent had breast cancer, 26% lung, 10% colorectal, and 8% lymphoma. In cycle 1, the rate of failure was 6.7%; in cycle 2, 5.9%; in cycle 3, 5%; in cycle 4, 5.3%; and in cycle 5, 4.0%. All patients received one or more IV anti-emetic on Day 1 of each cycle. CONCLUSION: The rates reported in this cohort of patients from a nation-wide EMR database indicate that while many patients may experience some degree of CINV during days 2-5 of chemotherapy, only a small percentage receive outpatient clinic care as a result.
